Evercore ISI lowered Bio-Techne's price target to $54 from $68, maintaining an "In Line" rating. This change reflects an update in outlook, alongside recent product expansions and conference presentations.

NodeGuardian

2026-04-17 07:07:20

Abstract generation in progress

Evercore ISI has revised its price target for Bio-Techne (NASDAQ: TECH) down to $54 from $68, while keeping an “In Line” rating on the stock. This adjustment reflects a change in the analyst’s outlook for the biotechnology and medical research company. The article also lists recent news regarding Bio-Techne, including product expansions and presentations at healthcare conferences.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
181.05K Popularity
#
Gate13thAnniversaryLive
587.45K Popularity
#
AltcoinsRallyStrong
7.31M Popularity
#
AnthropicvsOpenAIHeatsUp
1.06M Popularity
#
KalshiFacesNevadaRegulatoryClash
455.06K Popularity

Sitemap

Evercore ISI Adjusts Price Target on Bio-Techne to $54 From $68, Maintains In Line Rating

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin